NeurogesX’ NGX 4010 MAA Filed And Accepted For Review By EMEA For Treatment Of Peripheral Neuropathic Pain

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing novel pain management therapies, announced that the Marketing Authorization Application (MAA) submitted by NeurogesX for NGX-4010, the Company’s lead product candidate for peripheral neuropathic pain, has been accepted for review by the European Medicines Agency (EMEA). [click link for full article]

More: continued here

Filed under: Clinical Trials on September 28th, 2007